# Pediatrix Medical Group, Inc. (MD)

> Source: Nexqual · https://nexqual.com/MD · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Pediatrix Medical Group, Inc. (MD), nexqual.com/MD" · informational, not investment advice.

**Price:** USD 29.55 (+5.16% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 28.1 · day 28.11–29.68 · 52w 16.89–29.69 · market cap $2.40B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $1.95B, net income $175M (9.0% margin) (SEC filings).
- Valuation: P/E 13.7x (avg 11.0x at the last 1 fiscal year-ends), EV/EBITDA 10.0x, net cash $6.1M.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $856K; 1 not under a Rule 10b5-1 plan ($856K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.86 on a 1–5 scale) (7 analysts), mean target USD 26.33 (range 21–28).
- Total return with dividends: 1Y +72.1% vs S&P 500 +14.9%; 5Y +9.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 0.65, revenue estimate $498M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.91B | $1.97B | $1.99B | $2.01B | $1.91B | $1.95B |
| Operating income | $203M | $173M | $7.3M | -$68.7M | $209M | $215M |
| Net income | $131M | $66.3M | -$60.4M | -$99.1M | $165M | $175M |
| EPS (diluted) | $1.53 | $0.79 | -$0.73 | -$1.19 | $1.94 | — |
| Operating margin | 10.6% | 8.8% | 0.4% | -3.4% | 10.9% | 11.0% |
| Net margin | 6.9% | 3.4% | -3.0% | -4.9% | 8.6% | 9.0% |
| Revenue growth | +10.2% | +3.2% | +1.1% | +0.9% | -4.9% | — |
| Cash + short-term investments | $487M | $103M | $178M | $349M | $500M | — |
| Total debt | $990M | $637M | $622M | $611M | $571M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 13.7x · P/S 1.2x · EV/EBITDA 10.0x · EV/Sales 1.2x · P/B 2.7x · Earnings yield 7.28% · Buyback yield (TTM) 6.21% · Net cash $6.1M · EV $2.39B
P/E at fiscal year-ends: Dec 2025 11.0x.

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-13 | Weis Shirley A | Director | 36,028 | $856K | 65.9% | No | Too little history (no open-market trades in 2024 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.86 on a 1–5 scale), 7 analysts; mean target USD 26.33 (low 21, high 28).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-19 | Jefferies | Downgrade | Buy → Hold | $27 → $28 |
| 2026-08-06 | UBS | Target raised | Neutral | $25 → $28 |
| 2026-07-14 | Truist Securities | Target raised | Hold | $23 → $28 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +72.1% | +9.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +72.4% | +1.8% |
| Volatility (annualized) | 41.1% | 42.3% |
| Max drawdown | -23.6% (Nov 2025→Feb 2026) | -76.3% (Nov 2021→Jul 2024) |

## Peers (Medical Care Facilities)
BKD (Brookdale Senior Living Inc.) USD 10.19 +1.09% · GRDN (Guardian Pharmacy Services, Inc) USD 39.59 +1.56% · ADUS (Addus HomeCare Corporation) USD 122.67 +4.00% · SGRY (Surgery Partners, Inc.) USD 15.9 +3.25% · AVAH (Aveanna Healthcare Holdings Inc) USD 13.32 +2.54% · ACHC (Acadia Healthcare Company, Inc.) USD 31.88 +1.43%

## More
Full page: https://nexqual.com/MD · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Health Care Patient Service | $418.7M | 85.8% | +5.4% |
| Hospitals Contracts | $68.3M | 14.0% | +0.1% |
| Product & Service Other | $779,000 | 0.2% | -75.7% |
| Total revenue | $487.8M | 100% | — |

## Company outlook (8-K filed 2026-08-04)

- "A reconciliation of projected full year 2026 Adjusted EBITDA to the most directly comparable GAAP financial measures is also provided in the financial tables of this press release."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.65 | $0.67 | -2.7% | $498.2M | 7 |
| Next quarter (ends 2026-12-31) | $0.63 | $0.58 | +8.0% | $499.1M | 7 |
| Current fiscal year (ends 2026-12-31) | $2.35 | $2.28 | +3.2% | $1.96B | 7 |
| Next fiscal year (ends 2027-12-31) | $2.44 | $2.36 | +3.5% | $2.01B | 6 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-10-29): ±14.9%; last 8 reports averaged ±11.3%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 65.7% | ±14.9% |
| 2026-12-18 | 56 | 53.2% | ±17.1% |
| 2027-02-19 | 119 | 56.0% | ±25.4% |
| 2027-05-21 | 210 | 50.4% | ±29.9% |